Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
出版年份 2013 全文链接
标题
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
作者
关键词
-
出版物
BLOOD
Volume 122, Issue 9, Pages 1634-1648
出版商
American Society of Hematology
发表日期
2013-06-22
DOI
10.1182/blood-2013-03-487728
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
- (2013) Vera Grossmann et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing
- (2012) S.-Y. Ko et al. CLINICAL MICROBIOLOGY AND INFECTION
- Application of next-generation sequencing technologies in virology
- (2012) A. D. Radford et al. JOURNAL OF GENERAL VIROLOGY
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
- (2011) W. T. Parker et al. BLOOD
- Mutational analysis in chronic myeloid leukemia: when and what to do?
- (2011) Susan Branford et al. CURRENT OPINION IN HEMATOLOGY
- Sensitive Detection ofBCR-ABL1Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
- (2011) Wendy T. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
- (2011) J. A. Schumacher et al. JOURNAL OF CLINICAL PATHOLOGY
- Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants
- (2011) S. Gianella et al. JOURNAL OF VIROLOGY
- The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories
- (2011) A Kohlmann et al. LEUKEMIA
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
- (2010) Elias Jabbour et al. CANCER
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history
- (2009) E Jabbour et al. LEUKEMIA
- SeaView Version 4: A Multiplatform Graphical User Interface for Sequence Alignment and Phylogenetic Tree Building
- (2009) M. Gouy et al. MOLECULAR BIOLOGY AND EVOLUTION
- Sequencing technologies — the next generation
- (2009) Michael L. Metzker NATURE REVIEWS GENETICS
- Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid Leukemia
- (2009) Elias Jabbour et al. SEMINARS IN HEMATOLOGY
- Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
- (2008) T. Ernst et al. HAEMATOLOGICA
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia
- (2008) J S Khorashad et al. JOURNAL OF CLINICAL PATHOLOGY
- High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain
- (2008) Kateřina Machová Poláková et al. LEUKEMIA RESEARCH
- Next-generation DNA sequencing
- (2008) Jay Shendure et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started